3 recruiting, 1 completed, 1 not yet recruiting. 3 Phase 1, 3 Phase 2.
By phase and status
Follow L19IL2: new trials by email Literature Review of L19IL2 trials Research Report on L19IL2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
L19IL2, L19TNF, L19IL2/L19TNF - Locally Advanced Basal Cell Carcinoma | Phase 2 | Recruiting | Philogen S.p.A. | 180 | 2026-06-01 | 2026-07-31 |
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
L19IL2, Ruxolitinib - Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic | Phase 1 | Not yet recruiting | Philogen S.p.A. | 96 | 2026-05-01 | 2026-05-05 |
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
[177Lu]Lu-OncoFAP-23, L19IL2 - FAP | Phase 1 | Recruiting | Philogen S.p.A. | 56 | 2025-10-31 | 2026-10-26 |
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
L19IL2, L19TNF, L19IL2/L19TNF - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | Philogen S.p.A. | 162 | 2024-07-12 | 2026-09-02 |
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
L19IL2 - Advanced Solid Tumours | Phase 1 / Phase 2 | Completed | Philogen S.p.A. | 33 | 2005-11-01 | 2014-02-25 |
Conditions studied
Carcinoma, Basal Cell (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Melanoma (1)
Sponsors
Philogen S.p.A. (5)
Countries
Italy (5) · Germany (3) · United States (2) · Greece (1) · Spain (1)
Top investigators
Danielle Bello (1) · Filippo De Braud, Dr (1) · Manfred Johannsen, Dr (1)
Results publications
PMID 20797845
NIH funding
2025 (2), 2005 (1), 2023 (1)